as 06-17-2025 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | NEWARK |
Market Cap: | 2.9B | IPO Year: | 2016 |
Target Price: | $67.11 | AVG Volume (30 days): | 860.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.86 | EPS Growth: | -68.10 |
52 Week Low/High: | $30.67 - $60.60 | Next Earning Date: | 08-05-2025 |
Revenue: | $207,801,000 | Revenue Growth: | -34.02% |
Revenue Growth (this year): | -81.42% | Revenue Growth (next year): | 52.36% |
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
MT Newswires
20 hours ago
Argus Research
7 days ago
The Wall Street Journal
9 days ago
Simply Wall St.
13 days ago
MT Newswires
16 days ago
Business Wire
17 days ago
Insider Monkey
22 days ago
ACCESS Newswire
a month ago
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.